Prohost Biotech - Exclusive Biotech Research ~ A Comprehensive Resource for Biotech News

bluebird bio: Why This Firm’s Stock Gained $6.37 Yesterday

June 14, 2019 0

Why has bluebird bio Been Hammered in the Market Recently? Investors should be asking why bluebird bio (BLUE) has been hammered in the market recently before asking why the stock gained $6.37 in trading yesterday. Why was it subjected to a selloff a few days ago? Why? When you consider the announcement of conditional marketing authorization, granted from the European …

Novartis: Psoriatic Arthritis Patients on Cosentyx Had No Radiologic Progression...

bluebird bio Announces a European Conditional Approval of Its Gene...

Cara Therapeutics: More Positive Results from the Korsuva Product Trial...

Vertex: Good News and Good Decisions

Advaxis: Why This Small Firm’s Stock Outperformed on a Negative...

Will the Bear Escape Tonight from the Market? Regeneron and...

Bluebird bio and Celgene: Encouraging Clinical Trial Results for Last...

Exelixis and Aerie Have Good News

Gilead and insitro announce strategic collaboration to discover and develop...

Regeneron and Alnylam collaborative agreement will benefit these firms so...

Sangamo’s stock price Soars 52% in pre-market hours on hemophilia...

Aimmune Therapeutics’ product AR101 for the treatment of peanut allergy...

The FDA approves the first ever postpartum depression product. Positive...

Atossa Genetics’ news that staged a huge Rally of this...

Spark Therapeutics to be acquired by Roche at $113.47 UP $61.91

Merck’s product Keytruda and Exelixis’ product Cabometyx are both winners

RegenxBio: An analyst and investor event focused on the firm’s...

Successful results were announced by uniQure for its gene therapy,...

RegenxBio product RGX-181 has been granted FDA Rare Pediatric Disease...

Today’s Highlights

Nektar Product NKTR-358 Shows Promise in Autoimmune and Chronic Inflammatory Conditions

June 13, 2019 0

Nektar Announced Results for NKTR-358 During an oral session at the Annual European Congress of Rheumatology …

Why Vertex’s and CRISPR Therapeutics’ Stocks Are Rallying

June 7, 2019 0

Vertex and CRISPR Therapeutics While some groups are doubting the gene editing capability of CRISPR gene …

Gilead Sciences: Improving the Safety and Efficacy of Yescarta® CAR T

June 6, 2019 0

AT ASCO Gilead Sciences and Yescarta® By Acquiring Kite Pharma Gilead Sciences(GILD) gained Kite’s CAR T technology …

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

June 4, 2019 0

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is …

Recent News from Incyte, Merck and Nektar

May 29, 2019 0

Incyte's FDA Approval Based on encouraging data from the REACH1 trial the FDA approved a label …

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

May 24, 2019 0

Amgen, the Biotech King Amgen (AMGN), the biotech king, wanted to buy all of the Denmark …

Array BioPharma: Great News and a Learning Experience

May 21, 2019 0

Great News for Array BioPharma Array BioPharma (ARRY) announced positive results from the interim analysis of …

The Medicines Company: Are Inclisiran’s Clinical Trial Results Impressive?

May 21, 2019 0

The Medicines Company Are Inclisiran's Clinical Trial Results Impressive? Our answer is YES. The trial results …

Another Late-Stage Firm with Impressive Technology and Promising Products

May 16, 2019 0

About Iovance Biotherapeutics Iovance Biotherapeutics (IOVA) is a late-stage biotechnology company developing novel cancer immunotherapies based on …

Regeneron: Why the FDA Approval of EYLEA for Diabetic Retinopathy is Extremely Important.

May 14, 2019 0

The FDA Approval of Regeneron's EYLEA Is Important The PANORAMA Trial of EYLEA for Diabetic Retinopathy …

The Week in Review

The Week in Review #40

April 16, 2019 0

Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at …

During the Departed Week

March 19, 2019 0

The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …

Good news and setbacks during the departed week

March 5, 2019 0

The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …

The Week in Review #37

February 19, 2019 0

From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …

Now You See It, Now You Don’t

January 28, 2019 0

Now You See it, Now You Don’t Deliberate Omissions of Real Facts Real facts might be …

Politics and the Market

December 11, 2018 0

The Week in Review #35 Politics and the Market The market tumbled today as Theresa May, …

Improving on immunotherapy and preventing one of its serious side effects

November 13, 2018 0

The Week in Review #34 Improving on Immunotherapy and preventing one of its serious side effects. …

We call it the bad market

October 30, 2018 0

The Week in Review #33 WE CALL IT THE BAD MARKET The Federal Reserve’s raising of …

Positive News

October 22, 2018 0

The Week in Review #32 POSITIVE NEWS PROTEOSTASIS THERAPEUTICS Cystic Fibrosis Two days ago, a clinical-stage …

Outperformance, underperformance and volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Prohost Letters

The ASCO 2019 Special Edition

June 11, 2019 0

Prohost Letter #432 The ASCO 2019 Special Edition SPRAYING FEAR The Victims Are The most disturbed …

Genomes, Genes and Gene Therapies

May 28, 2019 0

Prohost Letter #431 Genomes, Genes and Gene Therapies In this issue of the Prohost Letter we …

Prohost Letter #430

April 5, 2019 0

Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary …

End of the Year Decisions ~ Part 4

March 14, 2019 0

Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …

End of the Year Decisions ~ Part 3

February 10, 2019 0

Prohost Letter #428 End of the Year Decisions ~ Part 3 In Part 3 of this …

End of the Year Decisions Part 2

January 24, 2019 0

Prohost Letter #427 End of the Year Decisions ~ Part 2 As a result of the unexpected …

End of the Year Decisions ~ Part 1

January 15, 2019 1

Prohost Letter #426 End of the Year Decisions ~ Part 1 We decided to make this …

The NEW Prohost Portfolio for 2019

January 3, 2019 0

The NEW Prohost Portfolio Small Important Changes We are making some very small but important changes …

When common sense fails to explain market performance

December 3, 2018 0

Prohost Letter #425 When Common Sense Fails to Explain the Market Performance It is not unusual …

Following the Stars. Less Science and More Logic

October 14, 2018 0

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …